ERBB2 and breast carcinoma: Importantly, recent studies have reported the long-term effects of trastuzumab administered alone or in combination with chemotherapy to HER2-positive breast cancer patients, all showing a significant effect of this drug on disease-free survival and overall survival [92,93,94].